Selon l'OCDE, la Norvège devrait renforcer les incitations à travailler plus longtemps

La Norvège est mieux armée que la plupart des autres pays pour faire face au vieillissement de la population.

Also Available

• Norway should improve incentives to encourage people to work longer, says OECD
• Norge bør styrke insentivene til å jobbe lengre for eldre arbeidstakere, sier OECD

OECD Health Working Paper No. 56. Description of Alternative Approaches to Measure and Place a Value on Hospital Products in Seven OECD Countries

To assess the feasibility of using secondary data sets information to feed an output-based PPP approach for hospital services, we reviewed the main characteristics of diagnoses and procedures coding standards, DRG classification systems, and cost-finding methods used in selected OECD countries.

Related Documents

• No. 53 - Comparing Price Levels of Hospital Services Across Countries: Results of Pilot Study

OECD Health Working Paper No. 55: Mortality Amenable to Health Care in 31 OECD Countries: Estimates and Methodological Issues

The mortality amenable to health care is defined as a possible indicator to measure the health care systems performance in preventing premature deaths that can be avoided by appropriate health care intervention. This paper assesses the feasibility of using this indicator in OECD countries.

A System of Health Accounts: Implementation - Norway

Information on the status of implementation of OECD's System of Health Accounts in Norway.

Creation and Governance of Human Genetic Research Databases

Summarises proceedings of a conference looking at examples of human genetic research databases, how they are established, how they are managed and governed, how they might be commercialised, and what the policy considerations might be.

Related Documents

• Guidelines for Human Biobanks and Genetic Research Databases (HBGRDs)

Innovation in Pharmaceutical Biotechnology: Comparing National Innovation Systems at the Sectoral Level

This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries. Based on rich evidence, it draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.

Related Documents

• Sectoral Case Studies in Innovation: Pharmaceutical biotechnology
• Pharmacogenetics: Opportunities and Challenges for Health Innovation